Palo Alto Investors LP - Q1 2024 holdings

$887 Million is the total value of Palo Alto Investors LP's 38 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 100.0% .

 Value Shares↓ Weighting
ExitSIGHT SCIENCES INC$0-173,790
-100.0%
-0.08%
VNDA ExitVANDA PHARMACEUTICALS INC$0-278,985
-100.0%
-0.11%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Biomarin Pharmaceuticals, Inc45Q2 202416.6%
UNITED THERAPEUTICS CORP DEL45Q2 202415.3%
INSMED INC45Q2 202416.6%
STAAR Surgical Company45Q2 202411.8%
AMICUS THERAPEUTICS INC45Q2 202413.3%
PROTHENA CORP PLC45Q2 20249.1%
VANDA PHARMACEUTICALS INC43Q4 20235.8%
CYTOKINETICS INC43Q2 20240.9%
ALIGN TECHNOLOGY INC42Q2 20242.5%
ABIOMED INC38Q3 202217.1%

View Palo Alto Investors LP's complete holdings history.

Latest significant ownerships (13-D/G)
Palo Alto Investors LP Q1 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
eHealth, Inc.February 14, 20242,739,3799.7%
Karyopharm Therapeutics Inc.February 14, 20245,102,1934.4%
Revance Therapeutics, Inc.February 14, 20245,237,2846.0%
ALIMERA SCIENCES INCSold outApril 03, 202300.0%
Epizyme, Inc.Sold outFebruary 14, 202300.0%
INSMED IncFebruary 14, 20235,871,2914.3%
Vanda Pharmaceuticals Inc.February 14, 20231,087,0641.4%
ALIMERA SCIENCES INCFebruary 14, 2022802,42311.6%
Clovis Oncology, Inc.February 14, 20223,997,8263.1%
STAAR SURGICAL COFebruary 14, 20221,140,5112.4%

View Palo Alto Investors LP's complete significant-ownership history.

Latest filings
TypeFiled
N-PX2024-08-29
13F-HR2024-08-14
13F-HR2024-05-15
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14

View Palo Alto Investors LP's complete filings history.

Compare quarters

Export Palo Alto Investors LP's holdings